612501-80-1

Basic information

• Product Name: 6-Quinazolinol, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-, acetate (ester), monohydrochloride
• Synonyms: 6-acetoxy-4-(3-chloro-2-fluoroanilino)-7-methoxyquinazoline hydrochloride
• CAS NO: 612501-80-1
• Molecular Formula: C17H13ClFN3O3.ClH
• Molecular Weight: 398.221
• Mol File: 612501-80-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 6-Quinazolinol, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-, acetate (ester), monohydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Quinazolinol, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-, acetate (ester), monohydrochloride(612501-80-1)
• EPA Substance Registry System: 6-Quinazolinol, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-, acetate (ester), monohydrochloride(612501-80-1)

Safety Data

• Hazardous Substances Data: 612501-80-1(Hazardous Substances Data)

Upstream product

• 2106-04-9 3-chloro-2-fluoroaniline 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 

Downstream Products

• 1441145-46-5 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylethyl)piperidin-4-yl]oxy}quinazoline 
• 1441145-65-8 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)azetidin-3-yl]oxy}quinazoline 
• 612501-81-2 tert-butyl 4-((4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate 
• 848942-61-0 Sapitinib 
• 612500-78-4 N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(piperidin-4-yloxy)quinazolin-4-amine 
• 1441146-12-8 tert-butyl [4-({4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]propionate 
• 1441146-93-5 6-{[(1-tert-butoxycarbonyl)azetidin-3-yl]oxy}-4-(3-chloro-2-fluoroanilino)-7-methoxyquinazoline 
• 1441146-99-1 6-(azetidin-3-yloxy)-4-(3-chloro-2-fluoroanilino)-7-methoxyquinazoline 
• 1441145-10-3 4-(3-chloro-2-fluoroanilino)-6-{[1-(N-isopropylcarbamoylmethyl)piperidin-4-yl]oxy}-7-methoxyquinazoline 
• 848942-78-9 4-(3-chloro-2-fluoroanilino)-6-{[1-(N,N-dimethylcarbamoylmethyl)piperidin-4-yl]oxy}-7-methoxyquinazoline 
• 1626387-81-2 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2S)-2,4-dimethylpiperazine-1-carboxylate 
• 1626387-80-1 (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl-2,4-dimethylpiperazinyl-1-carboxylic acid ester 

Relevant articles and documents

Substituted quinazoline compound, pharmaceutical composition containing substituted quinazoline compound, and applications of substituted quinazoline compound

The invention relates to a substituted quinazoline compound, a pharmaceutical composition containing the compound, and applications of the compound, wherein the substituted quinazoline compound with ageneral formula (I) and the pharmaceutically acceptable salt thereof have excellent brain barrier permeability, enhanced metabolic stability and long metabolic half-life period, show high inhibitoryactivity on activated or drug-resistant mutant form EGFR compared with wild type EGFR, and can effectively reduce side effects.

Discovery of AZD8931, an equipotent, reversible inhibitor of signaling by EGFR, HER2, and HER3 receptors

Deregulation of HER family signaling promotes proliferation and tumor cell survival and has been described in many human cancers. Simultaneous, equipotent inhibition of EGFR-, HER2-, and HER3-mediated signaling may be of clinical utility in cancer settings where the selective EGFR or HER2 therapeutic agents are ineffective or only modestly active. We describe the discovery of AZD8931 (2), an equipotent, reversible inhibitor of EGFR-, HER2-, and HER3-mediated signaling and the structure-activity relationships within this series. Docking studies based on a model of the HER2 kinase domain helped rationalize the increased HER2 activity seen with the methyl acetamide side chain present in AZD8931. AZD8931 exhibited good pharmacokinetics in preclinical species and showed superior activity in the LoVo tumor growth efficacy model compared to close analogues. AZD8931 is currently being evaluated in human clinical trials for the treatment of cancer.

PIPERIDYL-QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS

The invention concerns quinazoline derivatives of formula (I) wherein R1and R2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB, particularly EGF, receptor tyrosine kinases.